Customize your JAMA Network experience by selecting one or more topics from the list below.
Incorrect Drug Trade Names: In the Special
Communication entitled "The Seventh Report of the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:
the JNC 7 Report" published in the May 21, 2003, issue of THE JOURNAL (2003;289:2560-2572),
there were incorrect drug trade names in Table 4 and Table 5 . On page 2566,
in Table 4 , the trade name "Tevetan" should have read "Teveten" and on page
2567, in Table 5 , the trade name "Aldactone" should have read "Aldactazide."
In addition, on page 2565, in column 1, the first full sentence should have
read "When BP is more than 20 mm Hg above the systolic BP goal or 10 mm Hg
above the diastolic BP goal, consideration should be given to initiating therapy
with 2 drugs, either as separate prescriptions or in fixed-dose combinations
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report—Correction. JAMA. 2003;290(2):197. doi:10.1001/jama.290.2.197
Create a personal account or sign in to: